Alto Neuroscience Inc
ANRO3.600USD
-0.510-12.41%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
97.46MValor de mercado
PerdaP/L TTM
Mais detalhes de Alto Neuroscience Inc Empresa
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
Informações da empresa
Código da empresaANRO
Nome da EmpresaAlto Neuroscience Inc
Data de listagemFeb 02, 2024
CEODr. Amit Etkin, M.D., Ph.D.
Número de funcionários76
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 02
Endereço650 Castro Street, Suite 450
CidadeMOUNTAIN VIEW
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal94041
Telefone17732555012
Sitehttps://www.altoneuroscience.com/
Código da empresaANRO
Data de listagemFeb 02, 2024
CEODr. Amit Etkin, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Ms. Gwill York
Ms. Gwill York
Independent Director
Independent Director
--
--
Mr. Nicholas (Nick) Smith
Mr. Nicholas (Nick) Smith
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Hanley
Mr. Michael Hanley
Chief Operating Officer
Chief Operating Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Alpha Wave Global, LP
13.69%
Armistice Capital LLC
6.00%
Point72 Asset Management, L.P.
4.91%
Etkin (Amit)
4.45%
Franklin Advisers, Inc.
4.29%
Outro
66.65%
Investidores
Investidores
Proporção
Alpha Wave Global, LP
13.69%
Armistice Capital LLC
6.00%
Point72 Asset Management, L.P.
4.91%
Etkin (Amit)
4.45%
Franklin Advisers, Inc.
4.29%
Outro
66.65%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
19.52%
Hedge Fund
14.77%
Venture Capital
13.80%
Investment Advisor
13.64%
Individual Investor
7.48%
Research Firm
1.06%
Private Equity
0.92%
Family Office
0.24%
Endowment Fund
0.08%
Outro
28.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
175
22.95M
84.78%
-8.18M
2025Q1
171
24.58M
90.79%
-9.93M
2024Q4
154
26.22M
97.22%
-2.96M
2024Q3
131
26.77M
99.31%
+3.33M
2024Q2
102
22.89M
85.38%
+1.53M
2024Q1
71
21.11M
78.78%
+8.14M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Alpha Wave Global, LP
3.71M
13.7%
--
--
Mar 31, 2025
Armistice Capital LLC
1.60M
5.91%
+950.00K
+146.15%
Mar 31, 2025
Point72 Asset Management, L.P.
1.24M
4.58%
-452.10K
-26.72%
Mar 31, 2025
Etkin (Amit)
1.21M
4.45%
--
--
Mar 17, 2025
Franklin Advisers, Inc.
1.16M
4.29%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.22M
4.5%
-11.02K
-0.90%
Mar 31, 2025
Vestal Point Capital, LP
915.00K
3.38%
--
--
Mar 31, 2025
Marshall Wace LLP
852.99K
3.15%
+15.62K
+1.86%
Mar 31, 2025
Cox (Christopher Nixon)
715.65K
2.64%
--
--
Mar 17, 2025
72 Investment Holdings, LLC
667.78K
2.47%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
